Obalon Therapeutics, Inc.

Robbins LLP Is Investigating the Officers and Directors of Obalon Therapeutics, Inc. (OBLN) on Behalf of Shareholders

February 13, 2018 (San Diego, CA & Carlsbad, CA) – Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of Obalon Therapeutics, Inc. (NasdaqGM: OBLN) breached their fiduciary duties to shareholders.  Obalon, a vertically integrated medical device company, develops and commercializes medical devices to treat obese and overweight people by facilitating weight loss.

Obalon Therapeutics, Inc. (OBLN) Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies send us a message via the
Shareholder Information form below.



Send us a message for more information.

Skip to content